Kailera Completed Enrollment for Obesity Drug Trials
The Phase 3 clinical program for the weight loss medication ribupatide has moved into its active treatment phase.
Updated on Sept. 30, 2026 in Weight Loss
Live Poll
Should medical treatments be the primary focus for managing obesity in the U.S.?
Kailera Therapeutics has finalized enrollment for its global Phase 3 clinical program, which is testing the efficacy and safety of the weight management medication ribupatide. The study involves approximately 4,900 adult participants across 11 countries.
Why it matters
As the demand for obesity treatments rises globally, these trials are critical for establishing the performance of new once-weekly injectable therapies. The results will help determine if this medication offers a viable long-term option for patients managing weight-related health risks.
The KaiNETIC Phase 3 program includes three separate clinical trials involving a combined 4,900 adults. The studies evaluate a once-weekly subcutaneous injection of ribupatide at doses up to 10 mg over a 76-week period.
The players
Kailera Therapeutics
A biotechnology company focused on the development of metabolic therapies, including weight management treatments.
Hengrui
A pharmaceutical developer that granted global commercialization rights for ribupatide to Kailera.
The details
Ribupatide is a dual agonist that targets both GLP-1 and GIP receptors, which are proteins involved in the regulation of appetite and metabolism. The study protocols utilize a dose titration period lasting up to 24 weeks, followed by a maintenance phase of at least 52 weeks to assess drug performance. By mimicking these naturally occurring hormones, the therapy aims to influence weight loss through sustained biological signaling.
Timeline
May 2024: Kailera acquired global rights for ribupatide.
September 30, 2026: Enrollment for the KaiNETIC clinical program was completed.
First half 2027: Planned initiation of Phase 3 trials for oral ribupatide.
Mid-2028: Topline clinical trial data is expected to be released.
Health Landscape
The development of ribupatide builds upon the success of recent dual-hormone therapies used to treat obesity and metabolic conditions. This program represents a significant expansion of the clinical pipeline for injectable weight loss medications currently in development.
These results will eventually provide evidence on the long-term safety and effectiveness of dual-agonist weight loss therapies. If you are exploring weight management options, keep a record of your health history to discuss potential treatment evolutions with your physician.
The takeaway
Clinical trial programs are essential for determining the safety profile of new weight loss medications before they are available for patient use. Talk to your primary care physician about current, evidence-based treatments if you are actively managing your weight.
What happens next
Topline data from the KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3 trials is expected in mid-2028.
Further reading
For more on the current landscape of metabolic health, visit our Weight Loss section.
Live Poll
Should medical treatments be the primary focus for managing obesity in the U.S.?
